No Data
Allist Pharmaceuticals 2024 Profit Jumps 122%, Revenue Rises 76%
Fumetinib drives performance growth, Shanghai Allist Pharmaceuticals Co., Ltd. expects net profit to increase by over 120% year-on-year in 2024.
① During the reporting period, Shanghai Allist Pharmaceuticals Co., Ltd. achieved revenue of 3.558 billion yuan, a year-on-year increase of 76.29%; net income attributable to shareholders was 1.43 billion yuan, up 121.97% year-on-year, and net income excluding extraordinary items was 1.361 billion yuan, an increase of 124.51% year-on-year; ② The net cash flow reached 1.566 billion yuan, a growth of 132.12% compared to 0.675 billion yuan in the same period last year. Ample funds are beneficial for expanding R&D investment.
Alice: 2024 Annual Report of Shanghai Alice Pharmaceutical Technology Co., Ltd.
Alice: Shanghai Alice Pharmaceutical Technology Co., Ltd. Report for the first quarter of 2025
Alice: Summary of the 2024 Annual Report of Shanghai Alice Pharmaceutical Technology Co., Ltd.
Shanghai Allist Pharmaceuticals Co., Ltd. 2024 Annual Report
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shareholders Might Be Looking For Exit
